Büyüme Hormonu Eksikliği Olan Çocuklarda Klasik Büyüme Hormonu Tedavisi Dozunu Azaltmak Mümkün mü?

Abstract

Amaç: Düşük doz büyüme hormon tedavisi ile sağlanabilecek maddi kazanç ihtimalini ortaya koymak için bu çalışma planlandı. Olgular ve Metod: Büyüme hormonu eksikliği olan 97 çocuk 2 grupta incelendi. 1)Çalışma grubuna (n=39) rekombinant insan büyüme hormonu (rhGH) 0.15 mg/kg/ hafta dozunda verildi. 2)Kontrol grubuna (n=58), rhGH klasik doz olan 0.2 mg/kg / hafta dozunda verildi. Tüm olgular çalışma başlangıcında ve büyüme hormon tedavisinin 6. ve 12.aylarında değerlendirilip oksolojik kontrolleri yapıldı ve insülin benzeri büyüme faktörü (IGF-1) ile insülin benzeri büyüme faktörü bağlayıcı protein -3 (IGFBP-3) seviyeleri ölçüldü. Bulgular: Kontrol grubu ile karşılaştırıldığında çalışma grubunda: Tedavinin 6.ayında IGF-1, IGFBP3, büyüme hızı (GV) ve büyüme hızı SDS (GVSDS) değerlerinde istatistiksel anlamlı fark bulunamazken, tedavinin 12.ayında kontrol grubunda GV ve GVSDS seviyeleri anlamlı yüksek bulundu. Bu fark kontrol grubunda bu dönemde gözlenen pubertal sıçramaya bağlandı. Her 2 grupta; GV ve GVSDS ile parental boy, hedef boy, IGF-1, IGFBP-3 değerleri arasında istatistiksel anlamlı fark bulunamadı. Sonuç: Büyüme hormonu tedavisinde halen kullanılmakta olan konvansiyonel dozun azaltılması büyüme üzerinde anlamlı olumsuz etki yapmadığından daha düşük doz tedavi ile tedavi maliyetlerinde yaklaşık %20 civarında azalma sağlanabilir ki, bu tüm ülkeler için total tedavi harcamalarını azaltmada çok önemli bir kazanç olabilir.

Keywords

• Büyüme hormonu tedavisi, IGF1, IGFBP3

IS IT POSSIBLE TO DECREASE THE CONVENTIONAL GROWTH HORMONE DOSAGE IN GROWTH-DEFICIENT CHILDREN?

Abstract

Objective: The prospect of financial savings by decreasing growth hormone dose, prompted us to study the effectiveness of lower dose treatment. Subjects and methods: We studied 97 growth hormone deficient (GHD) children in two groups: 1) The study group (n=39) was treated with recombinant human GH (rhGH) at a low dose of 0.15 mg/kg/week 2) The control group (n=58) was treated with rhGH, at a conventional dose of 0.2 mg/kg/week. All patients were evaluated for auxology, Insulin like growth factor-1(IGF-1) and Insulin like growth factor binding protein-3(IGFBP3) levels at baseline, 6 and 12 months after starting GH therapy. Results: While there was no significant difference in IGF-1, IGFBP3, growth velocity (GV), and growth velocity SDS (GVSDS) levels after 6 months of therapy between the two groups, the GV and GVSDS levels were significantly higher in the control group after 12 months. This difference contributed to significant pubertal spurt in the control group. In both groups, no significant correlation was found among parental heights, target heights, IGF-1 and IGFBP3 levels with GV and GVSDS. Conclusion: By decreasing the conventional GH treatment dose, we also decrease the cost of GH treatment approximately by 20% which may lead to an important cut in the treatment related cost

Keywords

• Growth hormone replacement therapy, IGF-1, IGFBP3

References

1. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measure- ments during GH treatment of GH-deficient and non-GH-deficient child- ren and adolescents. Horm Res. 2001; 55:115-24.
2. Cianfarani S, Liguori A, Germani D. IGF-I and IGFBP-3 assessment set growth hormone deficiency. Endocr Dev 2005;9:66-75. 12- Radetti G, D’Addato G, Gatti D, Bozzola M, Adami S. Influence of two different GH dosage regimens on final height, bone geometry and bonestrengthinGH-deficientchildren. Eur J Endocrinol 2006;154: 479- 82. of chilhood on
3. Rosenfeld RG. Editorial: the Pharmacogenomics of human growth. J Endocrinol Metabol 2006; 91:795-796.
4. Kelnar CJ. Postponing puberty in children with growth hormone defici- ency. J Pediatr Endocrinol Metab 2005;18:533-534.
5. Van Dijk M, mulder P, Houdijk M, Mulder J, Noordam K, Odink RJ, Rongen-Westerlaken C, Voohoeve P, Waelkens J, Stovvis-Brantsma, Hokken-Koelega A. High serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) during high-dose GH treatment in short children born small for gestational age. J Clin Endocrinol Metab 2006; 91: 1390-1396.
6. Ranke M, Guilbaud O. Growth response in prepubertal children with idi- opatic growth hormone deficiency during the first two years of treatment with human growth hormone. Analysis of the Kabi Pharmacia International Growth Study. Acta Paediatr Scand Suppl 1991; 379: 109-115.
7. Blethen SL, Compton P, Lippe BM, Rosenfeld GR, August GP, Johansson A. Factors predicting the response to growth hormone (GH) therapy in children with GH deficiency. J Clin Endocrinol Metab. 1993; 76: 574- 579.
8. Kriström B, Jansson C, Rosberg S, Albertsson-Wikland K. Growth respon- se to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. J Clin Endocrinol Metab. 1997; 82: 2889-2898.

9. Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, Ross JL, Casorla FG, Wolka AM, Wit JM, Rekers-Mombarg LT, Cutler GB Jr. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005;90:5188-5196.
10. Graves DA. Utility of the National Cooperative Growth Study database for safety reporting. J Pediatr 1996;128:1-3.
11. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin- like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393- 1396.
12. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999; 51: 34-41.
13. Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP. Body composition and quality of life in adults with growth hormone defi- ciency; effects of low-dose growth hormone replacement. Clin Endocrinol 2001; 54: 709-717.
14. Rikken B, Van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF- binding protein-3 in the evaluation of childhood growth hormone defici- ency. Horm Res 1998;50:166-176.
15. Pozo J, Martos-Moreno GA, Barrios V, Argente J. The IGF system in childhood: physiology and clinical implications. J Endocrinol Invest 2005;28:38-42.
16. Schwarze CP, Wollmann HA, Binder G, Ranke MB. Short-term increments of insulin- like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH- sensivite children. Acta Paediatr 1999; 428: 200-208.
17. Hibi I, Tanaka T, Tanae A, Kagawa J, Hashimato N, Yoshizawa A, Shizume K. The influence of gonadal function and effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children. J Clin Endocrinol Metab.1989; 69: 221-226
18. Tanaka T, Yoshizawa A, Tanae A, Hibi I, Shizume K. Relationships bet- ween puberty growth at adolesence in-growth-hormone-deficient males: effect of growth hormone and of associated gonadal suppression therapy. Horm Res. 1990; 33: 102-105.
19. Frisch H, Birnbacher R. Final height and pubertal devolopment in children with growth hormone deficiency after long-term treatment. Hormon Res. 1995; 43: 132-134.
20. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and fi- nal height in patients with severe GH deficiency. J Clin Endocrinol Metab. 2006; 91: 1076-1080.